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Abstract
Background: The commonest pathogenic DMD changes are intragenic deletions/duplications
which make up to 78% of all cases and point mutations (roughly 20%) detectable through direct
sequencing. The remaining mutations (about 2%) are thought to be pure intronic rearrangements/
mutations or 5'-3' UTR changes. In order to screen the huge DMD gene for all types of copy
number variation mutations we designed a novel custom high density comparative genomic
hybridisation array which contains the full genomic region of the DMD gene and spans from 100 kb
upstream to 100 kb downstream of the 2.2 Mb DMD gene.
Results: We studied 12 DMD/BMD patients who either had no detectable mutations or carried
previously identified quantitative pathogenic changes in the DMD gene. We validated the array on
patients with previously known mutations as well as unaffected controls, we identified three novel
pure intronic rearrangements and we defined all the mutation breakpoints both in the introns and
in the 3' UTR region. We also detected a novel polymorphic intron 2 deletion/duplication variation.
Despite the high resolution of this approach, RNA studies were required to confirm the functional
significance of the intronic mutations identified by CGH. In addition, RNA analysis identified three
intronic pathogenic variations affecting splicing which had not been detected by the CGH analysis.
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Conclusion: This novel technology represents an effective high throughput tool to identify both
common and rarer DMD rearrangements. RNA studies are required in order to validate the
significance of the CGH array findings. The combination of these tools will fully cover the
identification of causative DMD rearrangements in both coding and non-coding regions, particularly
in patients in whom standard although extensive techniques are unable to detect a mutation.
Background
The DMD gene was the first gene identified by reverse
genetics. Mutations in the gene cause Duchenne (DMD)
and Becker (BMD) muscular dystrophies. Both the fre-
quency and devastating nature of these conditions make
DMD one of the most extensively studied genes among
the rare genetic disorders [1-3].
This intense research has provided molecular tools for the
identification of the causative mutation in about 98% of
patients, combining MLPA to detect exonic deletions/
duplications (75–80% of mutations) and direct sequenc-
ing to identify small mutations (up to 20% of mutations).
Nevertheless, some mutations remain unidentified. Fur-
thermore it is well known that the large size (2.2 Mb) of
the gene makes it prone to complex rearrangements which
are impossible to define precisely using routine molecular
diagnostic techniques.
As a consequence, there are a considerable number of
DMD/BMD patients in whom no causative mutation has
been identified. This impacts on genetic diagnosis, genetic
prognosis, clinical confirmation, carrier detection, prena-
tal diagnosis and genetic counselling for the families
involved.
Furthermore, the recent opportunities in terms of innova-
tive therapeutic approaches [4,5] highlight the relevance
for patients and families of obtaining a correct molecular
diagnosis, which is required in order to be included in
innovative trials. Indeed the increased availability of
experimental but highly mutation specific therapies, sum-
marised in the concept of "personalised medicine" [6,7],
makes the identification of private mutations in the DMD
gene necessary to be eligible for these trials.
In the last few years genome scanning technologies have
enabled the detection of previously unrecognised large
(>1 kb) copy-number variations (CNVs) in human DNA.
While many of these variants do exist as polymorphisms,
some of them can change the copy number of critical
genes or genomic regions, or alter gene regulation and
underlie monogenic disorders, developmental abnormal-
ities and a variety of complex genetic disorders [8-11].
Therefore there is a wide consensus on the potential of
array-CGH to determine CNVs for research and clinical
purposes, in terms of providing robust and precise meas-
urement of CNVs, scalability and very high resolution
[12].
Although CGH was initially considered as a strategy for
improving cytogenetic resolution by detecting fine chro-
mosome imbalances [13,14], recently other applications
have been envisaged such as cancer studies [15], complex
syndromes, mental retardation, Mendelian disorders and
polygenic traits [16].
The flexibility of CGH arrays is also due to the availability
of both commercial and custom arrays, which are
designed on demand, therefore it is possible to investigate
any region of interest with the appropriate resolution.
Dhami et al. [2] designed a single strand PCR-based CGH
array in order to detect exon deletions/duplications in a
few genes, including DMD.
This strategy demonstrated the ability to identify CNVs,
however, in the same way as MLPA and other techniques,
it only investigated coding regions.
We have applied the CGH technique in a novel full-gene
approach which investigates the presence of CNVs in the
entire genomic region of the DMD  gene. Our custom
designed high density-comparative genomic hybridisa-
tion array (DMD-CGH) based on in situ synthesis of 60
mer probes with intervals of 260 bp, allowed us to obtain
a full map of CNVs in the gene, including the non coding
regions which have not been investigated previously.
Our studies allowed us to validate our array for accurately
detecting previously identified rearrangements, to define
intronic breakpoints precisely and to identify three patho-
genic purely intronic CNVs. We corroborated the CGH
studies by RNA analysis, therefore validating the signifi-
cance of the gene imbalances identified. Transcription
analysis of the full DMD transcript furthermore disclosed
three rare splicing mutations due to small intronic
changes, missed by the CGH analysis.
Results
DMD-CGH array analysis
We firstly validated the DMD-CGH array both on ten nor-
mal control males and on four patients (1, 2, 3 and 4)BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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with mutations previously characterised by MLPA (Figure
1a–d). In patient 1, we detected two non-contiguous
duplications, one of 116 kb from intron 1P to intron 2
and including exon 2 and the other of 37 kb in intron 2
(Figure 1a). Patient 2 showed a deletion of 3569 bp, from
intron 13 to exon 14 (Figure 1b).
We also precisely defined the breakpoint in BMD patient
number 3, carrying an out of frame exon 3–6 duplication
and representing an exception to the rule [17]. The DMD
CGH array identified a duplication of 111 kb from intron
2 to nt 45 of exon 6, removing its 5'donor splice site con-
sensus sequences (Figure 1c).
In patient 4, with a duplication of exons 65–79 and a
DMD phenotype with associated severe mental retarda-
tion, the array allowed us to define the 3' breakpoint
within the 3' UTR. The mutation consists of a duplication
of 89 kb ranging from intron 64 to 241 bp downstream of
the DMD stop codon within the 3' UTR (Figure 1d).
The DMD-CGH allowed us to identify the causative rear-
rangements in three out of eight DMD patients previously
negative for DMD mutations.
We identified a 4 kb duplication in intron 55 located 12
kb upstream of exon 56 (patient 5, Figure 2a); two non-
contiguous deletions of 98 kb in intron 44 and 4 kb in
intron 45 (patient 6, Figure 2b); and a duplication of 1.3
kb in intron 4 located 11 kb from exon 5 (patient 7, Figure
2c). In the remaining five patients (8; 9; 10; 11; 12) no
pathogenic CNVs were identified by CGH.
Interestingly in all 12 patients the DMD-CGH array iden-
tified a CNV of 1.4 kb in intron 2 which was deleted in
patients 10 and 11 and duplicated in all the others (Figure
1a and 1c). Examples of deleted and duplicated alleles of
the intron 2 CNV are reported in Figure 3.
CGH analysis of ten normal control males revealed the
presence of both deleted and duplicated regions, therefore
suggesting this to be a polymorphic CNV (data not
shown).
Real Time PCR was performed in patients 5 and 7 while
PCR and sequencing were performed in patients 6, 10 and
11, validating the duplications and deletions identified
with the array (data not shown).
RNA analysis and sequence analysis
Patients with pathogenic CNVs identified at the DMD-CGH array 
analysis
Patient 5 showed a 4 Kb duplication in intron 55 con-
firmed by RealTime PCR, but no RNA was available for
analysis to determine whether this variant was pathogenic
or not.
DMD-CGH array profiles of deletions and duplications in patients with known mutations, identified by MLPA Figure 1
DMD-CGH array profiles of deletions and duplications in patients with known mutations, identified by MLPA. 
a) case 1, duplication of exon 2; b) case 2, deletion of exon 14; c) case 3, duplication of exons 3–6; d) case 4, duplication of 
exons 65–79. In figure 1a and c the intron 2 CNV is visible around 32.9 Mb.BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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DMD-CGH analysis of patient 6 revealed two non-contig-
uous deletions located in intron 44 and intron 45. RNA
analysis showed skipping of exon 45 (data not shown).
Since no splicing defect was detected on genomic DNA
using FM-CSCE analysis this suggested that an inversion
could be responsible for the phenotype. Based on DMD-
CGH results PCR analysis was performed confirming the
occurrence of an inversion of the entire region with a dele-
tion of 98 kb (intron 44) and 4 kb (intron 45) at the
respective inversion breakpoints (Figure 4a and 4b).
Patient 7 showed a 1.3 kb duplication within intron 4.
The duplication was confirmed by RealTime PCR. RNA
analysis showed failure to amplify the exon 4–5 junction,
whereas exons 1 to 4 and exons 5 to 8 were correctly
spliced. PCR analysis with primers located within the
duplicated region coupled with primers in exons 4 and 5,
failed to detect any product. This behaviour suggests the
insertion of a very large intronic region into the transcript
between exons 4 and 5.
Patient 3 with BMD and the out-of-frame MLPA exons 3–
6 genomic duplication showed an in-frame exons 3–5
transcript, as expected considering the CGH results [17].
Patients negative for pathogenic CNVs at the DMD-CGH Array 
analysis
Patient 10 showed an insertion of 50 bp between exons 55
and 56, derived from intron 55 (Figure 5a). In this patient
the sequence of the intron 55 specific region showed an A
to G transition that lead to the creation of an acceptor
splice site (Figure 5b left). The recognition of a donor
splice site 50 nucleotides downstream results in the incor-
poration of the intronic sequence into the mature tran-
script, causing a frameshift. (Figure 5b right).
Patient 8 showed an insertion of 147 bp derived from
intron 65 between exons 65 and 66 (Figure 5a). In this
patient an A to G transition in intron 65 lead to the crea-
tion of a donor splice site (Figure 5c left). The presence of
an acceptor splice site 147 nucleotides upstream caused
the incorporation of the intronic region into the mature
transcript (Figure 5c right).
Patient 9 showed an insertion of 77 bp derived from
intron 37 between exons 37 and 38 (Figure 5a). This
sequence is normally present within intron 37 and
flanked by two cryptic splice sites. However a deletion of
18 nucleotides immediately upstream of the cryptic accep-
tor splice site also occurred in this patient, inducing the
recognition and incorporation of the abnormal out-of-
frame exon into the transcript (Figure 5d, left and right).
Intron 2 CNV
RNA analysis in both patients 8 (with the 1.4 duplication
in the same region) and 10 (with the 1.4 Kb deletion in
intron 2) showed a correct amplification of the transcript
including exon 2 and 3, therefore excluding a splicing
DMD-CGH array profiles of deletions and duplications in patients negative for DMD mutations Figure 2
DMD-CGH array profiles of deletions and duplications in patients negative for DMD mutations. a) case 5; b) case 
6; c) case 7.BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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abnormality as expected since the same CNV was also
found in the 10 unaffected males (data not shown).
All the results of the CGH study are reported in Table 1.
Discussion
The array CGH technique represents an extremely effec-
tive tool for the identification of CNVs in the genome with
important technical advantages (especially the large scale/
high resolution capacity) and relevant diagnostic implica-
tions. CGH array has been well validated in a variety of
approaches for defining both cytogenetic abnormalities
and some Mendelian disorders (CGH exon arrays). How-
ever, in the latter, non coding regions were never explored
[2].
Here we describe the results obtained using a novel cus-
tom DMD-CGH array covering the full genomic region of
the DMD gene, including 100 kb upstream and down-
stream of the 5' and 3' UTRs. We made this novel micro-
array in order to identify all possible quantitative
pathogenic changes in the DMD gene as well as elusive
deep intronic pathogenic CNVs. The DMD-array was able
to accurately identify and refine already known deletions/
duplications in the gene. This suggests that the array could
be used as a high throughput technique for high scale
DMD-CGH array profiles of intron 2 CNV Figure 3
DMD-CGH array profiles of intron 2 CNV. a) deleted allele and b) duplicated allele.BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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DMD molecular diagnosis. Remarkably it allowed us to
define both intronic and untranslated region (UTR)
breakpoints in all patients studied. It also revealed rare
pure intronic mutations which were not detected by rou-
tine genomic analysis. Notably, we describe a rare DMD
gene inversion affecting exon 45 [18], the first to be iden-
tified by CGH.
As expected, the array failed to identify very small intronic
mutations affecting splicing, for which RNA profiling was
necessary.
Among the patients studied, we identified three novel
pathogenic CNVs, which are purely intronic. RNA analysis
allowed us to demonstrate, at least for two of them, that
they affect the correct splicing of the DMD  gene. The
CGH-mediated identification of these rearrangements
avoided an extensive RNA analysis, often impaired by
low/poor quality of the RNA obtainable from patients' tis-
sues, in particular when only MyoD transformed myo-
genic cells are available.
DNA and RNA analysis in patients 10, 8 and 9 Figure 4
DNA and RNA analysis in patients 10, 8 and 9. a) RT-PCR analysis: the amplification of exons 52–57, 63–68, 35–40 
respectively, resulted in fragments larger than controls. b) Right: direct sequencing of the exons 52–57 amplification product in 
patient 10 showed an insertion of 50 bp (upper box) between exons 55 and 56, derived from intron 55; Left: sequence of the 
intron 55 specific region showed an A to G transition that lead to the creation of an acceptor splice site; c) Right: direct 
sequencing of the exons 63–68 amplification product in patient 8 showed an insertion of 147 bp (upper box) derived from 
intron 65 between exons 65 an 66; Left: sequence of the intron 65 specific region showed an A to G transition in intron 65 that 
result in the creation of a donor splice site; d) Right: direct sequencing of the exons 35–40 amplification product in patient 9 
showed an insertion of 77 bp (upper box) derived from intron 37 between exons 37 and 38; Left: the genomic sequence sur-
rounding the intron 37 region inserted into the mature transcript revealed the presence of a canonical acceptor and donor 
splice sites flanking the sequence itself. Moreover we identified a deletion of 18 nucleotides (reported in the box) which is 
located 20 nucleotides upstream in respect to the sequence inserted into the transcript.BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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By our DMD-CGH we also identified a non pathogenic
CNV within intron 2, not reported in the CNVs database
[19]. This was confirmed as a normal variant by transcrip-
tion analysis and by analysing normal controls.
Furthermore three complex rearrangements have been
defined in term of both orientation and breakpoint defi-
nition, again improving the molecular diagnosis. This for
example allowed better understanding of the genotype-
phenotype correlation in a BMD patient carrying an exons
3–6 out-of-frame duplication. The DMD-CGH array
showed that the 3' breakpoint falls within exon 6, provid-
ing a genomic basis for the observed splicing behaviour.
The DMD-CGH array may also help to investigate DMD/
BMD cases with additional features such as severe mental
retardation. Cognitive impairment in some DMD patients
has been associated with mutations affecting the distal
Dp140 and Dp71 dystrophin isoforms [20-22]. In our
patient with the rare duplication of exons 65–79 and
mental retardation, we confirmed the role of this distal
region in impairing dystrophin-related brain function
[20,23].
Furthermore the DMD-CGH array allowed us to reveal
that the breakpoint of the large duplication within the 3'
UTR involves a region containing seven AUF1 and two Hu
protein binding motifs. These proteins are well known to
be involved in mRNA stability [24]. It is conceivable that
large genomic changes within the 3'UTR of the DMD gene
may influence the resulting phenotype suggesting that the
3'UTR should be routinely investigated to possibly
unravel still unknown DMD  regulatory mechanisms
[21,25].
Considering these results, our DMD array promises to be
a useful tool both for DMD pathogenic CNV identifica-
tion and for refining the genomic configuration not only
in patients with unusual mutations but indeed in all
patients. In fact, while routine mutation analysis clearly
identifies apparently identical deletions in different
patients, in reality the intronic breakpoints will almost
invariably differ. This might involve motifs that affect
gene splicing in different ways [26].
Although the advantages of using the DMD-CGH array to
identify mutations are clear, RNA studies provided addi-
tional important information in these patients. In partic-
ular RNA studies allowed us to determine the significance
of the CNVs identified and also to see the effects on splic-
ing of mutations identified by the array. In addition the
RNA analysis allowed to identify small mutations affect-
ing splicing which had not been detected by the array.
Among these, we found three very unusual small deep
intronic mutations which would have required extensive
intronic sequencing to locate using standard methods. All
three were shown to alter the DMD splicing profile. In
particular, while the two point mutations creating a novel
cryptic splice site may be considered to be easily inter-
preted in terms of their effect on splicing, the small 18 bp
deletion within intron 37 is quite peculiar. In fact,
although the effect of this deletion on the transcript is evi-
dent, it is unclear how this novel genomic configuration
modifies the splicing machinery.
Genomic configuration in patient 6 Figure 5
Genomic configuration in patient 6. a) Schemes of the inverted genomic region including exon 45 in patient 6 and primers 
position. PCR amplification for the detection of inversion breakpoints was carried out using two forward primers (black 
arrows) and two reverse primers (grey arrows) surrounding the breakpoint regions; b) PCR results in patient 6: Lane 1 molec-
ular weight marker VI, Lane 2: proximal breakpoint (int44/int45(inv), Lane 3: distal breakpoint (int44(inv)/int45).BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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Conclusion
Our results suggest that this DMD-CGH array is a valua-
ble, cost-effective tool for high throughput DMD molecu-
lar diagnosis as well as for definition of elusive DMD gene
mutations. We suggest that the CGH genomic analysis
should precede RNA analysis in order to firstly define the
genomic profile.
In addition to the diagnostic implications, the investiga-
tion of non-coding regions as possibly implicated in the
etiopathogenesis of mutations in DMD but also in other
genetic disorders, may disclose findings of interest for
basic as well as applied research. Finally, the breakpoint
definition in large rearrangements, which has always rep-
resented an extremely complex task, will considerably
improve our understanding of the correlations between
genotype and phenotype.
Methods
Patients
We have studied 12 patients with DMD/BMD by the
DMD-CGH microarray, after obtaining informed consent
(Table 1). Four patients were already known to have rear-
rangements in the DMD gene identified by MLPA. One
Table 1: Summary of clinical, genomic and RNA data for analysed patients
Sample Clinical phenotype MLPA results Array results Array breakpoints Size of breakpoint RNA results
Controls
Pt 1 DMD dup ex2 dup (intron 
1P_intron 2)+ dup 
intron 2
chrX:g.(32,882,565_3
2,885,186)_(32,922,3
52_32,923,179)dup+ 
(32,936,752_32,938,6
81)_(33,055,162_33,
055,546)dup
37,166 + 116,481 r.(ex2)dup
Pt 2 BMD del ex14 del (intron 13_ex14) chrX:g.(32,501,829_3
2,502,002)_(32,505,5
71_32,505,939)del
3,569 Not available
Pt 3 BMD dup ex3_6 dup (intron 2_ex6) chrX:g.(32,744,336_3
2,744,610)_(32,855,9
33_32,856,897)dup
111,323 r.(ex3_5)dup
Pt 4 DMD plus MR dup ex65_79 dup (intron 64_*241) chrX:g.(31,049,450_3
1,049,716)_(31,138,8
70_31,139,129)dup
89,154 Not available
Patients
Pt 5 DMD NEG dup intron 55 chrX:g.(31,437,578_3
1,437,692)_(31,441,6
62_31,442,049)dup
3,970 Not available
Pt 6 DMD NEG del intron 44 + del 
intron 45
chrX:g.(31,890,926_3
1,891,072)_(31,894,8
74_31,894,891)del+ 
(31,950,161_31,950,6
11)_(32,048,920_32,
049,217)del
3,802 + 98,309 r.(ex45)del
Pt 7 DMD NEG dup intron 4 chrX:g.(32,762,962_3
2,763,096)_(32,764,4
72_32,764,484)dup
1,376 r.0(ex4_5)
Pt 8 DMD NEG NEG - - r.9563+1215A>G 
ins9563+1068_9563
+9563+1214
Pt 9 DMD NEG NEG - - r.(5325+1740_5325+
1757)del 
ins5325+1779_5325
+1839
Pt 10 DMD NEG NEG - - r.8217+18052A>G 
ins8217+18053_8217
+18102
Pt 11 DMD NEG NEG - - -
Pt 12 DMD NEG NEG - - -
DMD: Duchenne Muscular Dystrophy
BMD: Becker Muscular Dystrophy
MR: Mental Retardation
NEG: Negative
Pt: PatientBMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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DMD patient presented with mental retardation associ-
ated with a large duplication of exons 65–79. One BMD
patient had an out-of-frame duplication of exons 3–6 as
an exception to the reading frame rule, one DMD patient
showed an isolated duplication of exon 2, and one BMD
patient had a deletion of exon 14.
Eight DMD patients, fully analysed by MLPA and either
sequencing or FM-CSCE [27], had tested negative for
DMD mutations, despite protein studies using immuno-
histochemical and/or Western blot analysis indicating a
dystrophinopathy.
Ten normal control males were also tested on the DMD-
CGH array.
The study was approved by the local ethics committee
(approval number 9/2005).
Microarray design, hybridization and data analysis
DMD-CGH microarray design was performed using the
web based Agilent eArray database version 4.5 [28] (Agi-
lent Technologies, Santa Clara, CA). The high density
aCGH search function within eArray was used to turn the
genomic region chrX: 30947266–33367647 (March 2006
human reference sequence, NCBI Build 36.1, hg18) into a
probe set by selecting the maximum number of exonic
and intronic 60mer oligonucleotide CGH probes availa-
ble in the database. This probe set included 9293 probes
that were replicated twice in order to have both a technical
replicate and to reach the array format of 4 × 44 K, creating
four identical 44 K arrays on a single slide for simultane-
ous analysis of four different samples. 16 probes covering
the exons not included in the Agilent database were
designed specifically with eArray (v4.5) on the first exon
of Dp71 isoform and exons 49, 50, 61 and 78 and repli-
cated twice, achieving a final mean resolution of 260 bp.
The remaining spots on each 44 K array were filled with
probes from the X chromosome (11745) and all of the
autosomes (12053).
Labelling and hybridisation were performed following the
protocols provided by Agilent (Agilent Oligonucleotide
Array-Based CGH for Genomic DNA Analysis protocol
v5.0). The array was analysed with the Agilent scanner and
the Feature Extraction software (v9.1). A graphical over-
view and analysis of the data were obtained using the
CGH analytics software (v3.5). For identifying duplica-
tions and deletions we used the standard set-up of the
ADM-2 statistical analysis provided by CGH analytics
software. According to this set-up and in the case of X-
linked genes in males, deletions are visualised with values
of minus infinite (-4 in CGH analytics). The correspond-
ing value for duplications is +1. In general, al least 3 con-
secutive probes reaching these values are needed for a
positive call.
Real Time PCR
We confirmed the CNVs identified by the DMD-CGH by
Real time PCR analysis. Primer design on intronic regions
4 and 55 was performed by the Primer 3.0 on-line tool
[29] and checked for dimer formation with OLIGO 4.0-s.
Real-Time PCR was performed with Power SYBR® Green
PCR Master Mix (Applied Biosystems) according to the
protocol supplied (User Bullettin #2). The target sequence
was quantified with respect to an autosomal reference
sequence (GAPDH) and to a DMD exon known not to be
duplicated in the patient. In each experiment, control
female and male DNAs were used as calibrators.
RNA analysis
Transcription analysis of the DMD messenger RNA was
performed in six DMD and one BMD patients.
Total RNA was isolated from muscle biopsies using the
RNeasy Kit (Qiagen) following the manufacturer's
instructions. In patient 9 total RNA was isolated from
MyoD transformed fibroblasts as previously described
[30]. Before cDNA synthesis, RNA was treated with DNAse
I (Roche) and checked for residual DNA contamination
with a 55 cycle PCR.
Reverse transcription (RT) and PCR amplification were
performed using random hexanucleotide primers and
Superscript III enzyme (Invitrogen) according to the pro-
tocol supplied. All the PCR fragments were purified using
the QIAquick purification kit (QIAGEN) and sequenced
on an ABI Prism 3130.
In patients 3, 6 and 7 the transcription analysis was
focused on exons flanking the pathogenic rearrangement
detected by DMD-CGH (exons 2–7 for patient 3, exons
43–47 for patient 6, exons 3–6 for patient 7).
In patients 8, 9 and 10 the entire DMD transcript was
amplified in overlapping fragments of 750–800 bp (prim-
ers sequences are available upon request). For patients 5,
11 and 12 no muscle biopsies were available.
PCR genomic analysis
In patients 8, 9 and 10 we amplified the intronic regions
surrounding the sequences included in the mature tran-
script (introns 55, 65 and 37). DNA was extracted from
leukocytes by the Qiagen Biorobot.
In Patient 6 two forward primers were coupled in order to
amplify the centromeric inversion breakpoint and two
reverse primers were coupled in order to amplify the telo-
meric inversion breakpoint.BMC Genomics 2008, 9:572 http://www.biomedcentral.com/1471-2164/9/572
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PCR assays were performed with Ex Taq polymerase
(Takara), according to standard procedures. All the PCR
fragments were purified using the QIAquick purification
kit (QIAGEN) and sequenced on an ABI Prism 3130. All
the oligonucleotide sequences are available upon request.
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